Nov 18 2009, 11:40 AM EST
GEN News Highlights
Evotec received a research grant of up to €2.5 million (about $3.74 million) from the German government to fund R&D on serine racemase, a potential target in the field of neuroprotection. The grant will fund the company’s use of its compound library and fragment-based drug discovery platform to progress the project toward the clinic.
The money was awarded as part of Evotec’s involvement in the German government-supported Neu2 consortium. The consortium is focused on developing therapeutics against neurodegenerative diseases including multiple sclerosis.
Partners include Evotec, Merck Serono, the European ScreeningPort, Bionamics, and the University Medical Center Hamburg-Eppendorf.
♦♦♦
Related News
Boehringer Ingelheim Pledges $22.5M to Fund Another Four Years of Partnership with Evotec (Nov. 9, 2009)
Evotec Earns Roughly $3.75M as Seventh Milestone Fee from Boehringer Ingelheim (Oct. 22, 2009)
Ono to Use Evotec’s Ion-Channel Drug Discovery Platform in Expanded Deal (Oct. 15, 2009)
Biogen Idec Taps Evotec for Hit-Identification Research (Sep. 9, 2009)
Evotec Buys 70% of Indian Drug Discovery Services Firm for Over $4M (Aug. 6, 2009)
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More GEN News Highlights
Listen
Save
Comment
View All